Literature DB >> 16291826

Apoptosis induced by atRA in MEPM cells is mediated through activation of caspase and RAR.

Zengli Yu1, Jing Han, Jiuxiang Lin, Ying Xiao, Xingzhong Zhang, Yong Li.   

Abstract

We have previously demonstrated that all-trans retinoic (atRA) induced growth inhibition and apoptosis in mouse embryonic palate mesenchymal cells (MEPM). In the present study, we investigated the molecular mechanisms of atRA-induced apoptosis and its putative action pathway. atRA-induced apoptosis is associated with activation of the initiator caspase-9 and the effector caspase-3, but not of the effector caspase-8. A broad caspase inhibitor (z-VAD-fmk), caspase-9 inhibitor z-LEHD-fmk and caspase-3 inhibitor (z-DEVD-fmk) blocked atRA-induced DNA fragmentation and sub-G1 fraction, but not caspase-8 inhibitor z-IETD-fmk. We further showed that atRA dose-dependently promoted mRNA expression of retinoic acid receptor beta (RAR-beta) and gamma. A weaker increase in RAR-alpha mRNA was seen only at the highest concentration of atRA (5 muM). The pan RAR antagonist, BMS493, completely abrogated atRA-induced DNA fragmentation, Sub-G1 fraction, and caspase-3 activation. Taken together, these findings show that caspase-mediated induction of apoptosis by atRA is an RAR-dependent signaling pathway.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16291826     DOI: 10.1093/toxsci/kfj046

Source DB:  PubMed          Journal:  Toxicol Sci        ISSN: 1096-0929            Impact factor:   4.849


  2 in total

1.  All-trans retinoic acid inhibits migration, invasion and proliferation, and promotes apoptosis in glioma cells in vitro.

Authors:  Chen Liang; Ling Yang; Shiwen Guo
Journal:  Oncol Lett       Date:  2015-04-15       Impact factor: 2.967

2.  Metabolic characterization of all-trans-retinoic acid (ATRA)-induced craniofacial development of murine embryos using in vivo proton magnetic resonance spectroscopy.

Authors:  Feifei Qin; Zhiwei Shen; Lihong Peng; Renhua Wu; Xiao Hu; Guishan Zhang; Shijie Tang
Journal:  PLoS One       Date:  2014-05-09       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.